[HTML][HTML] Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …
[HTML][HTML] Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Q Sun, Z Hong, C Zhang, L Wang, Z Han… - Signal transduction and …, 2023 - nature.com
Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
BJ Schneider, J Naidoo, BD Santomasso… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …
recommended management of immune-related adverse events (irAEs) in patients treated …
Immune-related adverse events of checkpoint inhibitors
M Ramos-Casals, JR Brahmer, MK Callahan… - Nature reviews Disease …, 2020 - nature.com
Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
[HTML][HTML] Exosome-based immunotherapy: a promising approach for cancer treatment
Z Xu, S Zeng, Z Gong, Y Yan - Molecular cancer, 2020 - Springer
In the era of the rapid development of cancer immunotherapy, there is a high level of interest
in the application of cell-released small vesicles that stimulate the immune system. As cell …
in the application of cell-released small vesicles that stimulate the immune system. As cell …
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
RJ Sullivan, JS Weber - Nature reviews Drug discovery, 2022 - nature.com
The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …
inhibitors result in significant morbidity for patients as well as considerable cost to the health …
A review of cancer immunotherapy toxicity
LB Kennedy, AKS Salama - CA: a cancer journal for clinicians, 2020 - Wiley Online Library
Cancer immunotherapies, including checkpoint inhibitors and adoptive cell therapy,
manipulate the immune system to recognize and attack cancer cells. These therapies have …
manipulate the immune system to recognize and attack cancer cells. These therapies have …
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis
WM Wiersinga, KG Poppe… - The lancet Diabetes & …, 2023 - thelancet.com
Hyperthyroidism is a common condition with a global prevalence of 0· 2–1· 3%. When
clinical suspicion of hyperthyroidism arises, it should be confirmed by biochemical tests (eg …
clinical suspicion of hyperthyroidism arises, it should be confirmed by biochemical tests (eg …
Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing …
Importance Approximately 25% of patients with early-stage breast cancer who receive (neo)
adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy …
adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy …